No price history available.
Key financial summary
Financials in NOK| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | NOKm | 69 | 88 | 120 | 195 | 257 | 254 | N/A | N/A |
| Operating profit | NOKm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | NOKm | -102 | -126 | -137 | -107 | -123 | -135 | N/A | N/A |
| EPS reported | NOK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | NOK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | NOK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | NOK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | NOKm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | NOKm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | NOKm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | NOK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | NOK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in NOK| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Hofseth BioCare ASA, an international firm based in Norway, specializes in developing and supplying premium biomarine ingredients for both human and animal health. The company's product portfolio features various specialized offerings, including Brilliant salmon oil and OmeGo salmon oil, which promotes healthy cholesterol levels and supports cardiovascular well-being. ProGo, a salmon protein hydrolysate, serves as a rapidly assimilated protein supplement. For skeletal and joint health, Hofseth offers CalGo, a marine calcium powder. CollaGo, a collagen peptide powder, is designed to improve the appearance of hair, skin, and nails. Additionally, PetGo provides a non-soluble protein formulation. Distribution of these products is managed through a multi-channel approach, utilizing a network of distributors, agents, and its dedicated internal sales team. Hofseth BioCare also holds a significant research collaboration with Stanford University School of Medicine, focusing on pre-clinical and clinical studies related to conditions such as necrotizing enterocolitis and irritable bowel syndrome. Established in 2000, the company's main operations are based in Ålesund, Norway.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Hofseth BioCare ASA, an international firm based in Norway, specializes in developing and supplying premium biomarine ingredients for both human and animal health. The company's product portfolio features various specialized offerings, including Brilliant salmon oil and OmeGo salmon oil, which promotes healthy cholesterol levels and supports cardiovascular well-being. ProGo, a salmon protein hydrolysate, serves as a rapidly assimilated protein supplement. For skeletal and joint health, Hofseth offers CalGo, a marine calcium powder. CollaGo, a collagen peptide powder, is designed to improve the appearance of hair, skin, and nails. Additionally, PetGo provides a non-soluble protein formulation. Distribution of these products is managed through a multi-channel approach, utilizing a network of distributors, agents, and its dedicated internal sales team. Hofseth BioCare also holds a significant research collaboration with Stanford University School of Medicine, focusing on pre-clinical and clinical studies related to conditions such as necrotizing enterocolitis and irritable bowel syndrome. Established in 2000, the company's main operations are based in Ålesund, Norway.